NCT01820806View on ClinicalTrials.gov

Investigation of the Pharmacokinetics and Metabolism of GLPG0634 in Healthy Male Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

March 31, 2013

Primary Completion Date

April 30, 2013

Study Completion Date

April 30, 2013

Conditions
Healthy
Interventions
DRUG

100 mg dose of [14C] GLPG0634

Subjects will be dosed with a single oral 100 mg dose of \[14C\] GLPG0634 on one occasion

Trial Locations (1)

NG11 6JS

Quotient Clinical, Nottingham

Sponsors

Lead Sponsor

Galapagos NV
All Listed Sponsors
lead

Galapagos NV

INDUSTRY

NCT01820806 - Investigation of the Pharmacokinetics and Metabolism of GLPG0634 in Healthy Male Subjects | Biotech Hunter | Biotech Hunter